Literature DB >> 2161628

Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases.

T H Lee1, A E Crea, V Gant, B W Spur, B E Marron, K C Nicolaou, E Reardon, M Brezinski, C N Serhan.   

Abstract

Lipoxins are biologically active trihydroxytetraene containing products derived from arachidonic acid that are formed by interactions between lipoxygenases. Although the lipoxins have been generated from mixed cell suspensions in vitro, it has not been established whether these products are synthesized in vivo. We have performed bronchoalveolar lavage (BAL) in 12 patients with lung disease (sarcoid, six; pneumonia, two; asthma, two; carcinoma, one; alveolitis of unknown cause, one) and in six normal control subjects. The BAL fluid was analyzed for lipoxin A4 (LXA4) using gas chromatography mass spectrometry with selective ion monitoring, and the levels of the sulfidopeptide leukotrienes were determined using reverse-phase high-performance liquid chromatography and radioimmunoassay. LXA4 was detected in BAL fluid from nine of the 12 patients studied. The levels of LXA4 ranged from 0.4 to 2.8 ng/ml. LXA4 was not detected in any of the six normal subjects. Sulfidopeptide leukotrienes were detected in all the BAL samples, ranging from 0.04 to 0.7 ng/ml, and there was no significant difference between the patients and the normal subjects. In patients with detectable LXA4 in BAL fluid, the ratio of the concentrations of LXA4 to those of the sulfidopeptide leukotrienes ranged from 1.9 to 62 (mean, 19.0). This is the first demonstration of the presence of LXA4 in disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161628     DOI: 10.1164/ajrccm/141.6.1453

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  36 in total

1.  Lipoxins and other arachidonate derived mediators in bronchial asthma.

Authors:  C Chavis; I Vachier; P Godard; J Bousquet; P Chanez
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

2.  Barcelona's asthma epidemics.

Authors:  A Judd; J Docherty
Journal:  Thorax       Date:  1992-12       Impact factor: 9.139

3.  Diminished lipoxin biosynthesis in severe asthma.

Authors:  Bruce D Levy; Caroline Bonnans; Eric S Silverman; Lyle J Palmer; Gautham Marigowda; Elliot Israel
Journal:  Am J Respir Crit Care Med       Date:  2005-06-16       Impact factor: 21.405

Review 4.  Endogenous lipid mediators in the resolution of airway inflammation.

Authors:  O Haworth; B D Levy
Journal:  Eur Respir J       Date:  2007-11       Impact factor: 16.671

5.  Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo.

Authors:  C B Clish; J A O'Brien; K Gronert; G L Stahl; N A Petasis; C N Serhan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

6.  ALX receptor ligands define a biochemical endotype for severe asthma.

Authors:  Isabell Ricklefs; Ioanna Barkas; Melody G Duvall; Manuela Cernadas; Nicole L Grossman; Elliot Israel; Eugene R Bleecker; Mario Castro; Serpil C Erzurum; John V Fahy; Benjamin M Gaston; Loren C Denlinger; David T Mauger; Sally E Wenzel; Suzy A Comhair; Andrea M Coverstone; Merritt L Fajt; Annette T Hastie; Mats W Johansson; Michael C Peters; Brenda R Phillips; Bruce D Levy
Journal:  JCI Insight       Date:  2017-07-20

7.  Uncontrolled airway inflammation in lung disease represents a defect in counter-regulatory signaling.

Authors:  Anna Planaguma; Bruce D Levy
Journal:  Future Lipidol       Date:  2008

Review 8.  Lipoxins: resolutionary road.

Authors:  Paola Maderna; Catherine Godson
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

9.  Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma.

Authors:  Cindy Barnig; Manuela Cernadas; Stefanie Dutile; Xiaoli Liu; Mark A Perrella; Shamsah Kazani; Michael E Wechsler; Elliot Israel; Bruce D Levy
Journal:  Sci Transl Med       Date:  2013-02-27       Impact factor: 17.956

10.  Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma.

Authors:  Anna Planagumà; Shamsah Kazani; Gautham Marigowda; Oliver Haworth; Thomas J Mariani; Elliot Israel; Eugene R Bleecker; Douglas Curran-Everett; Serpil C Erzurum; William J Calhoun; Mario Castro; Kian Fan Chung; Benjamin Gaston; Nizar N Jarjour; William W Busse; Sally E Wenzel; Bruce D Levy
Journal:  Am J Respir Crit Care Med       Date:  2008-06-26       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.